Results 1 to 10 of about 910,008 (206)

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance [PDF]

Frontiers in Oncology, 2022
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusion has been identified as an oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer (NSCLC) with a frequency of approximately less than 1%.
Fangfang Liu, Yuxuan Wei, Huan Zhang, Jizong Jiang, Peng Zhang, Qian Chu   +5 more
doaj   +3 more sources

ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models [PDF]

Cell Reports
Summary: Pediatric-type high-grade gliomas frequently harbor gene fusions involving receptor tyrosine kinase genes, including neurotrophic tyrosine kinase receptor (NTRK) fusions.
Sebastian Schmid, Zachary R. Russell, Alex Shimura Yamashita, Madeline E. West, Abigail G. Parrish, Julia Walker, Dmytro Rudoy, James Z. Yan, David C. Quist, Betemariyam N. Gessesse, Neriah Alvinez, Kimberly D. Hill, Larry W. Anderson, Patrick J. Cimino, Debra K. Kumasaka, Ralph E. Parchment, Eric C. Holland, Frank Szulzewsky   +17 more
doaj   +4 more sources

Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan [PDF]

Cancer Medicine
Background Members of the neurotrophic tropomyosin receptor kinase (NTRK) gene family, NTRK1, NTRK2, and NTRK3 encode TRK receptor tyrosine kinases. Intra‐ or inter‐chromosomal gene rearrangements produce NTRK gene fusions encoding fusion proteins which ...
Eiji Nakata, Tatsunori Osone, Toru Ogawa, Tomoyuki Taguchi, Kana Hattori, Shinji Kohsaka   +5 more
doaj   +3 more sources

NTRK fusion in Japanese colorectal adenocarcinomas [PDF]

Scientific Reports, 2021
NTRK fusion-positive tumors are known to be highly sensitive to TRK inhibitors, such as larotrectinib and entrectinib. Therefore, identification of patients who can potentially benefit from these inhibitors is important; however, the frequency of NTRK ...
Yuya Yamashiro, Taisei Kurihara, Takuo Hayashi, Yoshiyuki Suehara, Takashi Yao, Shunsuke Kato, Tsuyoshi Saito   +6 more
doaj   +10 more sources

NTRK fusion promotes tumor migration and invasion through epithelial–mesenchymal transition and closely interacts with ECM1 and NOVA1 [PDF]

BMC Cancer
Background The NTRK fusion gene is a rare cancer driver and a typical representative "diamond mutation". Its unique role in tumor progression is highly important for the clinical diagnosis and treatment of patients with tumors.
Siqing Zeng, Ke Jiang, Jie Ge, Mimi Tang, Yuqi Wen, Xiaoting Ma, Heli Liu, Xingui Xiong   +7 more
doaj   +3 more sources

Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands. [PDF]

Mol Diagn Ther
Objectives: We evaluated the prognostic value of the neurotrophic tyrosine receptor kinase (NTRK) gene fusions by comparing the survival of patients with NTRK+ tumours with patients without NTRK+ tumours.
Santi I, Vellekoop H, M Versteegh M, A Huygens S, Dinjens WNM, Mölken MR.   +5 more
europepmc   +7 more sources

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population [PDF]

npj Precision Oncology, 2021
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are rare oncogenic drivers in solid tumours. This study aimed to interrogate a large real-world database of comprehensive genomic profiling data to describe the genomic landscape and prevalence
C. B. Westphalen, M. G. Krebs, C. Le Tourneau, E. S. Sokol, S. L. Maund, T. R. Wilson, D. X. Jin, J. Y. Newberg, D. Fabrizio, L. Veronese, M. Thomas, F. de Braud   +11 more
doaj   +2 more sources

NTRK fusion protein expression is absent in a large cohort of diffuse large B-cell lymphoma [PDF]

Frontiers in Oncology, 2023
BackgroundEven though two NTRK-targeting drugs are available for the treatment of irresectable, metastatic, or progressive NTRK-positive solid tumors, less is known about the role of NTRK fusions in lymphoma.
Susanne Ghandili, Judith Dierlamm, Carsten Bokemeyer, Clara Marie von Bargen, Sören Alexander Weidemann   +4 more
doaj   +2 more sources

NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report [PDF]

Frontiers in Oncology, 2023
Background: Neurotrophic tyrosine receptor kinase (NTRK) gene-fusion targeted molecules revolutionized the paradigm of treatment of a limited subgroup of cancers of various histologies.
Emanuela Palmerini, Giorgio Frega, Marco Gambarotti, Tommaso Frisoni, Marilena Cesari, Alberto Bazzocchi, Marco Miceli, Davide Maria Donati, Davide Maria Donati, Stefano Fanti, Cristina Nanni, Stefania Benini, Alessandra Longhi, Anna Paioli, Andrea Marrari, Rossella Hakim, Alberto Righi, Toni Ibrahim   +17 more
doaj   +3 more sources

Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report [PDF]

Case Reports in Oncology, 2021
While neurotrophic tropomyosin receptor kinase (NTRK) fusions represent rare oncogenic drivers (<1% of solid cancers), the recent approval of NTRK inhibitors (larotrectinib and entrectinib) led to dramatic responses in patients with NTRK fusion ...
Tyler Lanman, Melanie Hayden Gephart, Nam Bui, Angus Toland, Seema Nagpal   +4 more
doaj   +2 more sources